SEC Company Response from Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Jun 7, 2023

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: June 7, 2023 · CIK: 0001595097 · Accession: 0000950170-23-026822

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-272314

Date

June 7, 2023

Author

CORBUS PHARMACEUTICALS

Form

CORRESP

Company

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)

Letter

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive

Norwood, MA 02062

June 7, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:

Corbus Pharmaceuticals Holdings, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-272314)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on June 9, 2023, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff.

Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
CORBUS PHARMACEUTICALS

Show Raw Text

CORRESP
1
filename1.htm

  CORRESP

  Corbus Pharmaceuticals Holdings, Inc.

  500 River Ridge Drive

  Norwood, MA 02062

  June 7, 2023

  VIA EDGAR

  United States Securities and Exchange Commission

  Division of Corporation Finance

  100 F Street, N.E.

  Washington, D.C. 20549

    Re:

    Corbus Pharmaceuticals Holdings, Inc. (the “Company”)

  Registration Statement on Form S-3 (File No. 333-272314)

  Ladies and Gentlemen:

  In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on June 9, 2023, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff.

  Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.

    Very truly yours,

    CORBUS PHARMACEUTICALS

    HOLDINGS, INC.

    By:

    /s/ Sean Moran

    Name:

    Sean Moran

    Title:

    Chief Financial Officer

SecProbe.io